A Study of BV-araU in the Treatment of Varicella-Zoster Viral Disease (VZV) in HIV-Infected Children Who Have Not Had Success With or Who Cannot Take Other Treatments for VZV

Completed · Phase 3

Conditions studied: HIV Infections, Chickenpox

In brief

To provide oral sorivudine ( BV-araU ) to pediatric HIV-infected patients with varicella-zoster viral disease who have failed or are intolerant of alternative therapy.

Key facts

Study ID

NCT00002358

Run by

Bristol-Myers Squibb

Last updated by the study team

2007-10-02

Who can join

Age: 2 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must have:
• HIV infection.
• Cutaneous, visceral, or ocular varicella-zoster viral infection.
• Refractory or intolerant to acyclovir or foscarnet therapy.
• Consent of parent or guardian.

You may not qualify if…

• Co-existing Condition:
• Patients with the following symptoms or conditions are excluded:
• Inability to take oral capsules or tolerate liquids.
• Concurrent Medication:
• Excluded:
• 5-flucytosine, 5-fluorouracil, high-dose prednisone, or probenecid.
• Patients with the following prior condition are excluded:
• History of immediate hypersensitivity to nucleoside analogues.
• Prior Medication:
• Excluded:
• 5-flucytosine, 5-fluorouracil, high-dose prednisone, or probenecid within 4 weeks prior to study entry.
• Required:
• Prior acyclovir or foscarnet.

Where it is running

• Bristol - Myers Squibb Co — Wallingford, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.